Agenus Inc. (NASDAQ:AGEN) Short Interest Up 22.5% in December

Agenus Inc. (NASDAQ:AGEN) was the target of a large growth in short interest in December. As of December 31st, there was short interest totaling 3,399,217 shares, a growth of 22.5% from the December 15th total of 2,774,043 shares. Based on an average trading volume of 715,032 shares, the short-interest ratio is currently 4.8 days. Approximately 10.6% of the company’s stock are short sold. Approximately 10.6% of the company’s stock are short sold. Based on an average trading volume of 715,032 shares, the short-interest ratio is currently 4.8 days.

Agenus Stock Performance

Shares of NASDAQ AGEN opened at $3.34 on Tuesday. The firm’s 50 day moving average price is $3.88 and its 200 day moving average price is $4.40. The firm has a market cap of $113.59 million, a P/E ratio of -1.57 and a beta of 1.58. Agenus has a 1 year low of $1.38 and a 1 year high of $7.34.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Monday, November 10th. The biotechnology company reported $1.94 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.63 by ($0.69). The firm had revenue of $30.24 million during the quarter, compared to analyst estimates of $80.39 million. As a group, equities analysts predict that Agenus will post -12.55 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Agenus in a research note on Monday, December 29th. HC Wainwright reaffirmed a “buy” rating on shares of Agenus in a report on Monday, October 20th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $14.50.

Hedge Funds Weigh In On Agenus

Institutional investors and hedge funds have recently bought and sold shares of the stock. Traynor Capital Management Inc. acquired a new position in shares of Agenus in the 3rd quarter valued at $50,000. Catalyst Funds Management Pty Ltd acquired a new position in shares of Agenus in the 2nd quarter valued at about $50,000. Squarepoint Ops LLC purchased a new stake in shares of Agenus during the 3rd quarter worth about $54,000. Jump Financial LLC acquired a new position in Agenus during the second quarter valued at approximately $55,000. Finally, Acadian Asset Management LLC acquired a new position in Agenus during the first quarter valued at approximately $58,000. Institutional investors and hedge funds own 61.46% of the company’s stock.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.